Developer of innovative therapeutics intended to be used for the treatment of muscle disorders. The company utilizes an innovative and novel approach to target both cardiac and skeletal muscle weakness, enabling patients to avail disease-modifying drugs and therapies and stay fit and healthy.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Early Stage VC | 27-Feb-2017 | $8.43M | 00.00 | Completed | Startup | |
1. Early Stage VC (Series A) | 08-Jul-2015 | 000 | 000 | 000 | Completed | Startup |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 00.00 |
Name | Representing | Role | Since |
---|---|---|---|
Babar Ghias | Self | Board Member | 000 0000 |
John Kincaid | MyoTherix | Co-Founder & Board Member | 000 0000 |
Mark De Souza Ph.D | Self | Co-Founder, Chief Operating Officer & Chairman | 000 0000 |
Michael Kelly Ph.D | MyoTherix | Co-Founder, Chief Executive Officer, President & Board Member | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
CureDuchenne Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |